“Sustained moderate visual loss as a predictive end point for visual loss in non-proliferative diabetic retinopathy.”, Eye (Lond), vol. 23, no. 1, pp. 209-14, 2009.
, “Symptoms and Satisfaction of Patients in the Patient-Reported Outcomes With Laser In Situ Keratomileusis (PROWL) Studies.”, JAMA Ophthalmol, vol. 135, no. 1, pp. 13-22, 2017.
, , “Synagis® (Palivizumab) Prophylaxis of Respiratory Syncytial Virus (RSV) Infection - Patient Dempgraphics and Preliminary Results from 2000-2001 Synagis® Outcomes Registry”, J Perinatology, vol. 21, pp. 500-501, 2001.
, “Systems Vaccinology for a Live Attenuated Tularemia Vaccine Reveals Unique Transcriptional Signatures That Predict Humoral and Cellular Immune Responses.”, Vaccines (Basel), vol. 8, no. 1, 2019.
, , , “Tacrolimus ointment for the treatment of eyelid dermatitis”, Cutis, vol. 73, pp. 267-71, 2004.
, “Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas”, J Amer Acad Dermatology, vol. 48, pp. 564-8, 2003.
, “Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas.”, J Am Acad Dermatol, vol. 48, no. 4, pp. 564-8, 2003.
, “Tacrolimus Ointment is Effective for Facial and Intertriginous Psoriasis”, Journal of the American Academy of Dermatology, vol. 51, pp. 723-30, 2004.
, “Tacrolimus ointment is effective for facial and intertriginous psoriasis.”, J Am Acad Dermatol, vol. 51, no. 5, pp. 723-30, 2004.
, , “Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study.”, Pediatr Transplant, vol. 7, no. 3, pp. 217-22, 2003.
, “Tacrolimus vs cyclosporine A as primary immunosuppression in pediatric renal transplantation: A NAPRTCS study”, Pediatric Transplantation, vol. 7, pp. 217-222, 2003.
, , , “Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report.”, Am J Transplant, vol. 6, no. 6, pp. 1377-86, 2006.
, “Tacrolimus with Mycophenolate Mofetil (MMF) or Sirolimus vs. Cyclosporine with MMF in Cardiac Transplant Patients: 1-Year Report”, Am J Transplant, vol. 6, pp. 1377-1386, 2006.
, “Tacrolimus/Sirolimus vs Tacrolimus/Methotrexate as GVHD Prophylaxis After Matched, Related Donor Allogeneic HCT”, Blood, vol. 124, pp. 1372-1377, 2014.
, “Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.”, Blood, vol. 124, no. 8, pp. 1372-7, 2014.
, “Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS”, Blood, vol. 136, no. Supplement 1, pp. 32-33, 2020.
, “Ten-Year Follow-up of Age-Related Macular Degeneration in the Age-Related Eye Disease Study: AREDS Report No. 36”, JAMA Ophthalmol, vol. 132, pp. 272-277, 2014.
, “Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36.”, JAMA Ophthalmol, vol. 132, no. 3, pp. 272-7, 2014.
, “Ten-year incidence rates of age-related cataract in the Age-Related Eye Disease Study (AREDS): AREDS report no. 33.”, Ophthalmic Epidemiol, vol. 20, no. 2, pp. 71-81, 2013.
,